Network Medicine Flags 370 Existing Drugs as Possible Aging Modulators

TL;DR: A new *Nature Aging* study from Northeastern University and Harvard introduces a network-medicine pipeline that screened 6,442 approved or experimental drugs against the biological hallmarks of aging. It flagged 370 compounds with significant network proximity to aging biology and added a new transcription-based metric, pAGE, to separate likely *pro-longevity* drugs from potentially *age-accelerating* ones. The work is computational and hypothesis-generating — not clinical proof that any drug extends human life.

What did the study actually do?

Rather than testing drugs one by one, the team led by Bnaya Gross and Albert-László Barabási (with collaborators at Harvard Medical School and Brigham and Women's Hospital) used network medicine. They mapped 2,358 longevity-associated genes from the OpenGenes database onto the human interactome — a catalogue of 524,156 protein–protein interactions among 18,223 proteins.

Their first finding: the 1,250 genes tied to the 11 hallmarks of aging (such as epigenetic alterations, mitochondrial dysfunction, cellular senescence and altered intercellular communication) are not scattered randomly. They cluster into connected "hallmark modules" that sit in the same network neighbourhood — together forming a broader longevity module. Because aging genes occupy a defined neighbourhood, a drug can plausibly influence a hallmark by acting anywhere in that neighbourhood, not only on a single gene.

The researchers then measured how close each of 6,442 drugs from the DrugBank database sits to those hallmark modules ("network proximity"), and combined it with a second, novel metric.

The key advance: telling "good" from "bad"

Proximity alone tells you a drug *can* perturb a hallmark — not whether that is helpful or harmful. To fix this, the authors introduced pAGE (Pro-Age), a transcription-based score built on drug-induced gene-expression data. It checks whether a drug pushes gene activity *toward* a younger profile (pAGE > 0, pro-longevity) or *reinforces* age-related changes (pAGE < 0, potentially age-accelerating). Proximity plus pAGE form their SHARP pipeline.

How reliable are the predictions?

The pipeline was back-tested against drugs with real-world evidence. It reached 100% sensitivity for compounds shown to extend lifespan in mice (the NIA Interventions Testing Program) and 88.9% for compounds already in human longevity trials. It correctly surfaced familiar candidates: aspirin (predicted to touch six hallmarks), dasatinib (five), and the longevity drugs already under study — metformin, rapamycin and others, with rapamycin (sirolimus) mapping specifically to the intercellular-communication hallmark.

The nasal-spray headline, in context

The study's most quotable hit is oxymetazoline — the active ingredient in over-the-counter decongestant sprays (Afrin, Sinex) and a rosacea cream. SHARP predicts a *pro-longevity* effect (pAGE = 0.46) on the altered-intercellular-communication hallmark, because oxymetazoline targets ADRA1A, itself a high-confidence aging gene whose constitutive activation has been linked to lifespan extension in mice. Cell line experiments with Harvard are underway to test the prediction.

Important: this is a computational hypothesis, not a recommendation. Chronic use of decongestant nasal sprays causes rebound congestion and other harms, and no human longevity benefit has been demonstrated. Do not self-experiment.

What it means for longevity patients

Of the 370 flagged drugs, the 60 with expression data split into 21 likely pro-longevity candidates and 23 potential age-accelerators — a reminder that some widely used medicines might *speed* aspects of aging. For clinicians, a validated version of this approach could one day help weigh the longevity trade-offs of a prescription, and help prioritise which repurposing candidates are worth testing in cells, animals, and eventually trials. Patients interested in evidence-based, monitored protocols can explore longevity clinics worldwide.

Important caveats

As senior author Barabási put it, the work "does not provide a cure for aging, nor does it prove that any specific drug will extend human life. It offers a roadmap … toward actionable interventions that can be tested in cells, animals and eventually humans." The evidence is primarily computational; predictions rest largely on one cell line's expression data (MCF7) and do not yet account for dose or tissue-specific effects. Confirmation requires laboratory and animal studies followed by randomised controlled trials. (Two senior authors disclose they co-founded Scipher Medicine, a network-medicine company.)

*This article is for general information and is not medical advice. Do not start, stop, or change any medication based on early-stage research.*